Search Results - "Parikh, Divya Ahuja"

Addressing financial toxicity in urologic oncology patients by Parikh, Divya Ahuja, Srinivas, Sandy, Kerr, Elizabeth, Patel, Manali I.

“…Abstract only 170 Background: Financial toxicity, or the financial burden related to cancer care, is a source of distress for urologic oncology patients. This…”
Get full text

Comparison of perspectives and practices to mitigate financial toxicity between advance practice providers and attending oncologists by Ragavan, Meera Vimala, Parikh, Divya Ahuja, Patel, Manali I.

“…Abstract only 82 Background: Characterizing the oncology provider’s role in addressing the growing epidemic of financial toxicity faced by cancer patients is…”
Get full text

To Take or Not to Take a Side: That Is the Question by Parikh, Divya Ahuja, Lin, Albert Y

Get full text

Perspectives and practices of oncology providers in addressing financial toxicity by Ragavan, Meera Vimala, Parikh, Divya Ahuja, Patel, Manali I.

“…Abstract only e18342 Background: Few studies have evaluated the perspectives and clinical practices of oncology providers in regards to assisting patients with…”
Get full text

Evolving oncology provider perspectives on care delivery during the COVID-19 pandemic by Parikh, Divya Ahuja, Ragavan, Meera Vimala, Srinivas, Sandy, Garrigues, Sarah, Rosenthal, Eben Lloyd, Patel, Manali I.

“…Abstract only e18609 Background: The COVID-19 pandemic prompted rapid changes in cancer care delivery. We sought to examine oncology provider perspectives on…”
Get full text

Real world evidence comparison of first-line (1L) immune-oncology(IO)/tyrosine kinase inhibitor (TKI) vs. IO/IO combination therapy in renal cell carcinoma (RCC) by Bolan, Patrick, Hui, Gavin, Low, Yen, Gombar, Saurabh, Fan, Alice C., Parikh, Divya Ahuja, Shah, Sumit, Srinivas, Sandy, Khaki, Ali Raza

“…402 Background: IO/IO and IO/TKI are the preferred first-line combinations for treatment of RCC. While these combinations have been superior to sunitinib, no…”
Get full text

Real world outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177-PSMA-vipivotide tetraxetan (Lu177-PVT) by Bergstrom, Colin P, Song, Hong, Ruiz, Shann Mika, Chien, Joanne, Moore, Kaidi, Parikh, Divya Ahuja, Shah, Sumit, Fan, Alice C., Srinivas, Sandy, Iagaru, Andrei, Khaki, Ali Raza

“…86 Background: Lu177-PVT is a novel radioligand, which was recently approved by the FDA to treat mCRPC. Real world data on its use and efficacy is limited. We…”
Get full text

Financial toxicity among veterans with cancer by Parikh, Divya Ahuja, Ragavan, Meera Vimala, Khateeb, Sana, Patel, Manali I.

“…Abstract only 103 Background: Financial toxicity of cancer care has not previously been studied within the Veterans Health Administration (VHA). The VHA…”
Get full text

Understanding patient perspectives on window of opportunity clinical trials by Parikh, Divya Ahuja, Kody, Lisa, Brain, Susie, Heditsian, Diane, Lee, Vivian, Curtis, Christina, Sledge, George W., Caswell-Jin, Jennifer Lee

“…Abstract only 181 Background: In “window of opportunity” (WOO) clinical trials, people with newly diagnosed early-stage cancer are exposed to an experimental…”
Get full text

Demographic factors associated with financial toxicity: Results from the multisite cost study by Parikh, Divya Ahuja, Ragavan, Meera Vimala, Dutta, Ritika, Edwards, Jeffrey, Maitra, Debeshi, Patel, Manali I.

“…Abstract only e18362 Background: Financial toxicity (FT) is a major cause of distress for cancer patients. We have previously reported that FT was high among…”
Get full text

Cost-effectiveness of first-line therapy for advanced renal cell carcinoma in the immunotherapy era by Parikh, Divya Ahuja, Serrato, Paul Irvin, Srinivas, Sandy, Ryckman, Tess Sophie, Salomon, Joshua, Goldhaber-Fiebert, Jeremy D

“…Abstract only e19392 Background: The treatment landscape for advanced renal cell carcinoma (RCC) has transformed in the past two years. Both Nivolumab plus…”
Get full text

Coaches Activating Reaching and Engaging Patients (CAREPlan): A randomized controlled trial combining two evidence-based interventions to improve goals of care documentation by Parikh, Divya Ahuja, Asuncion, Mary Khay, Hansen, Jennifer, Seevaratnam, Briththa, Khateeb, Sana Indravadan, Rosenthal, Eben Lloyd, Teuteberg, Winifred, Patel, Manali I.

“…Abstract only 2 Background: In our prior work, community or lay health worker-led goals of care interventions improved goals of care documentation by…”
Get full text

Phase 2 open label study of durvalumab with neoadjuvant chemotherapy in variant histology bladder cancer by Khaki, Ali Raza, Fan, Alice C., Shah, Sumit, Parikh, Divya Ahuja, Chien, Joanne, Moore, Kaidi, Ruiz, Shann Mika, Haas, Denise, Fakhoury, Laith, Del Toro, Noël, Baker, Paige, O'Brien, Aidan, Srinivas, Sandy

“…524 Background: The immune-responsive nature of bladder cancer has made it an active area of interest for novel applications of immune checkpoint inhibitors…”
Get full text

Financial toxicity of cancer treatment at a diverse county hospital by Ahuja Parikh, Divya, Ragavan, Meera Vimala, Maitra, Debeshi, Aggarwal, Sangeeta, Patel, Manali I.

“…Abstract only 76 Background: The rising costs of cancer care increasingly results in financial distress for patients and their families. Low-income patients…”
Get full text

Financial toxicity of cancer treatment at a large academic cancer center by Ahuja Parikh, Divya, Amin, Krunal, Hall, Evan Thomas, Patel, Manali I.

“…Abstract only e18323 Background: Many studies have shown that patients with cancer are at higher risk of financial difficulty than those without cancer. Given…”
Get full text

Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer by Gupta, Divya, Fardeen, Touran, Teuteberg, Winifred, Seevaratnam, Briththa, Asuncion, Mary Khay, Alves, Nina, Rogers, Brian, Neal, Joel W., Fan, Alice C., Parikh, Divya Ahuja, Patel, Manali I., Shah, Sumit, Srinivas, Sandy, Huang, Jane E., Reddy, Sunil A., Ganjoo, Kristen N., Bui, Nam, Hansen, Jennifer, Gensheimer, Michael F., Ramchandran, Kavitha

“…Abstract only 8 Background: Patients with metastatic cancer benefit from advance care planning (ACP) conversations. Despite initiatives which train providers…”
Get full text

Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer by Golla, Vishnukamal, Shan, Yong, Farran, Elias J., Stewart, Courtney A., Vu, Kevin, Yu, Alexander, Khaki, Ali Raza, Parikh, Divya Ahuja, Swanson, Todd A., Keegan, Kirk A., Kamat, Ashish M., Tyler, Douglas S., Freedland, Stephen J., Williams, Stephen B.

“…•Total median costs were significantly higher for TMT than RC at 2-years ($372,839 vs. $191,363) and 5-years ($424,570 vs. $253,651), respectively.•TMT had…”
Get full text

Pathogenic germline mutations in emerging cancer genes: What happens after panel testing? by Hall, Evan Thomas, Ahuja Parikh, Divya, Gupta, Tanya, Caswell, Jennifer Lee, Mills, Meredith, Kingham, Kerry, Koff, Rachel, Ford, James M., Kurian, Allison W.

“…Abstract only 1528 Background: Next-generation sequencing technology enables more comprehensive germline genetic testing, including genes whose cancer risks…”
Get full text